AstraZeneca plc (ADR) AZN shares are trading higher by $1.00 at $27.28 in Friday's session. The primary catalyst for the rally is the announcement that the FDA has accepted duravalumab for priority review status.
Market News and Data brought to you by Benzinga APIsAlso, before the open, the company reported progress with it Alzheimer's drug it is developing with Eli Lilly and Co LLY. AstraZeneca was also upgraded by Leerink Swann from Market Perform to Outperform.
After a higher open, it retreated only a penny to $26.70 before continuing its move higher. The issue was halted at 9:54 a.m. at $27.11. Upon the reopen, it reached $27.42 before falling back to its current level. That coincides with its November 17 high of $27.41.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: BiotechLong IdeasHealth CareTechnicalsIntraday UpdateMoversTrading IdeasGeneralalzheimer'sDuravalumabLerrink Swann
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in